Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Finney

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Archives of Disease in Childhood|January 12, 2000
Reference ranges for plasma cystatin C and creatinine measurements in premature infants, neonates, and older childrenH Finney, D J Newman, H Thakkar, et al.
Journal of Bacteriology|July 27, 2002
Role of the C-terminal domain of the alpha subunit of RNA polymerase in LuxR-dependent transcriptional activation of the lux operon during quorum sensingAngela H Finney, Robert J Blick, Katsuhiko Murakami, et al.
Human Antibodies|March 13, 2008
Isolation and characterization of human antibodies targeting human aspartyl (asparaginyl) beta-hydroxylaseY A Yeung, A H Finney, I A Koyrakh, et al.
Cancer Medicine|January 6, 2015
Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research InstituteJohn D Hainsworth, Dana S Thompson, John A Bismayer, et al.
Advances in Hematology|January 25, 2012
In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33 Acute Myeloid LeukemiaA Dutour, V Marin, I Pizzitola, et al.
Circulation|February 2, 1999
PDGFbeta receptor blockade inhibits intimal hyperplasia in the baboonC E Hart, L W Kraiss, S Vergel, et al.
British Journal of Cancer|December 1, 1995
Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapyD J King, P Antoniw, R J Owens, et al.
Investigational New Drugs|February 25, 2015
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumorsJohanna C Bendell, Carla Kurkjian, Jeffrey R Infante, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Archives of Disease in Childhood|January 12, 2000
Reference ranges for plasma cystatin C and creatinine measurements in premature infants, neonates, and older childrenH Finney, D J Newman, H Thakkar, et al.
Journal of Bacteriology|July 27, 2002
Role of the C-terminal domain of the alpha subunit of RNA polymerase in LuxR-dependent transcriptional activation of the lux operon during quorum sensingAngela H Finney, Robert J Blick, Katsuhiko Murakami, et al.
Human Antibodies|March 13, 2008
Isolation and characterization of human antibodies targeting human aspartyl (asparaginyl) beta-hydroxylaseY A Yeung, A H Finney, I A Koyrakh, et al.
Cancer Medicine|January 6, 2015
Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research InstituteJohn D Hainsworth, Dana S Thompson, John A Bismayer, et al.
Advances in Hematology|January 25, 2012
In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33 Acute Myeloid LeukemiaA Dutour, V Marin, I Pizzitola, et al.
Circulation|February 2, 1999
PDGFbeta receptor blockade inhibits intimal hyperplasia in the baboonC E Hart, L W Kraiss, S Vergel, et al.
British Journal of Cancer|December 1, 1995
Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapyD J King, P Antoniw, R J Owens, et al.
Investigational New Drugs|February 25, 2015
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumorsJohanna C Bendell, Carla Kurkjian, Jeffrey R Infante, et al.
Pageof 2